Prostate Cancer : Episode 5

Video

Episode 5 - Pharmacoeconomic Considerations

During this discussion, Jeffrey D. Dunn, PharmD, MBA, explains how the rapid development of specialty drugs for the treatment of castration-resistant prostate cancer (CRPC) has increased the amount of pharmacoeconomic spending in the United States.

Because there are several options available, and because clinicians have different treatment preferences, Michael Kolodziej, MD, discusses why it is necessary to determine a proper sequencing plan before administering treatment.

Raoul S. Concepcion, MD, agrees that drug sequencing is a major challenge. However, he believes that because so many treatment options are available, clinicians need to individualize therapy when treating patients with CRPC.

Dr Dunn, Dr Concepcion, and David Quinn, MD, review the costs of new agents and discuss why it is important for insurers to provide coverage toward research that tests drug sequencing.


Related Videos
Dr Emma Achola-Kothani
Nini Wu, MD, Navista
Dr Emma Achola-Kothari
John Barkett, MBA
CK Wang, MD, COTA
John Barkett, MBA
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Eboni Price-Haywood, MD and Toni Flowers, PhD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo